MRC/UVRI & LSHTM Uganda Research Unit
Welcome,         Profile    Billing    Logout  
 5 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kaleebu, Pontiano
PrEPVacc, NCT04066881: A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP

Enrolling by invitation
2b
1668
RoW
Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48), Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48), Vaccine Group C: Saline placebo (weeks 0,4,24,48), Control PrEP:TDF/FTC once daily (weeks 0-26), Truvada, Experimental PrEP:TAF/FTC once daily (weeks 0-26), Descovy
MRC/UVRI and LSHTM Uganda Research Unit, Imperial College London, University College, London, International AIDS Vaccine Initiative, EuroVacc Foundation, Medical Research Council, South Africa, National Institute for Medical Research, Tanzania, Muhimbili University of Health and Allied Sciences, Instituto Nacional de Saúde, Mozambique, Ludwig-Maximilians - University of Munich, King's College London, Centre Hospitalier Universitaire Vaudois, Karolinska Institutet, CONRAD, Gilead Sciences
HIV Infections
12/24
12/24
NCT05064956: Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)

Completed
2
26
RoW
Ad26.ZEBOV, Zabdeno®
London School of Hygiene and Tropical Medicine
Ebola Virus Disease, Ebola, Hiv
11/21
10/22
HIV-CORE 006, NCT04553016: A Study to Test Three Experimental HIV Vaccines in Healthy Adults.

Active, not recruiting
1
88
RoW
Vaccine, Placebo
University of Oxford, European and Developing Countries Clinical Trials Partnership (EDCTP), University of Nairobi, KEMRI-Wellcome Trust Collaborative Research Program, MRC/UVRI & LSHTM Uganda Research Unit, International AIDS Vaccine Initiative, Imperial College London, Center for Family Health Research in Zambia
HIV-1-infection
11/22
11/22
COVAC-Uganda, NCT04934111: Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19

Recruiting
1
42
RoW
LNP-nCOV saRNA-02 Vaccine
MRC/UVRI and LSHTM Uganda Research Unit
COVID-19
11/22
12/22
EAPoC-VL, NCT05048472: East Africa Point of Care Viral Load Study

Recruiting
N/A
1440
RoW
Abbott HIV-1/2 VL Point of care Device
MRC/UVRI and LSHTM Uganda Research Unit, Karolinska Institutet, Kilimanjaro Christian Medical Centre, Tanzania, Amsterdam Institute for Global Health and Development, National Institute for Medical Research, Tanzania, Kenya Medical Research Institute, University of Rwanda
HIV, Viral Load, Point of Care Monitoring
08/24
02/25
Ruzagira, Eugene
IMPALA, NCT05546242: Improving HIV-1 Control in Africa With Long Acting Antiretrovirals

Recruiting
3b
540
RoW
Cabotegravir/Rilpivirine, Vocabria/Rekambys, Antiretroviral, 2NRTIs + dolutegravir 50mg once daily
MRC/UVRI and LSHTM Uganda Research Unit, Janssen Pharmaceuticals
HIV-1-infection
11/24
11/25
MOBILEMEN, NCT06133686: Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa

Not yet recruiting
3
400
NA
Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA), Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC)
MRC/UVRI and LSHTM Uganda Research Unit, King's College London, London School of Hygiene and Tropical Medicine, Africa Health Research Institute, Wits Health Consortium (Pty) Ltd, University College, London, Ministry of Health, Uganda, Desmond Tutu HIV Foundation, Assistance Publique - Hôpitaux de Paris
HIV
12/25
04/27
NCT05385510: Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV

Active, not recruiting
1
120
RoW
R21/Matrix-M™
University of Oxford, MRC/UVRI and LSHTM Uganda Research Unit
Malaria
09/25
09/25
Røge, Birgit
INSIGHT12, NCT04910269: Outpatient Treatment With Anti-Coronavirus Immunoglobulin

Recruiting
3
820
Europe, US, RoW
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
COVID, SARS-CoV2 Infection, Covid19
08/24
08/24
Kitonsa, Jonathan
COVAC-Uganda, NCT04934111: Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19

Recruiting
1
42
RoW
LNP-nCOV saRNA-02 Vaccine
MRC/UVRI and LSHTM Uganda Research Unit
COVID-19
11/22
12/22
ICC, London
NCT05822583: Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

Recruiting
4
1500
Europe, US, RoW
abatacept infusion, Placebo group
University of Minnesota
COVID-19
07/25
07/25
INSIGHT12, NCT04910269: Outpatient Treatment With Anti-Coronavirus Immunoglobulin

Recruiting
3
820
Europe, US, RoW
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
COVID, SARS-CoV2 Infection, Covid19
08/24
08/24
NCT05605093: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

Recruiting
3
1500
Europe, Japan, US, RoW
Shionogi Protease Inhibitor (S-217622), ensitrelvir, placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
07/25
07/25
Lutaakome, Joseph
INSIGHT12, NCT04910269: Outpatient Treatment With Anti-Coronavirus Immunoglobulin

Recruiting
3
820
Europe, US, RoW
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
COVID, SARS-CoV2 Infection, Covid19
08/24
08/24

Download Options